Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Current Leases (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Current Leases for 7 consecutive years, with $2.0 million as the latest value for Q1 2026.

  • For Q1 2026, Current Leases rose 2.3% year-over-year to $2.0 million; the TTM value through Mar 2026 reached $2.0 million, up 2.3%, while the annual FY2025 figure was $2.0 million, 5.36% up from the prior year.
  • Current Leases hit $2.0 million in Q1 2026 for Barinthus Biotherapeutics, down from $2.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.0 million in Q2 2025 and bottomed at $186000.0 in Q3 2022.
  • Average Current Leases over 5 years is $1.4 million, with a median of $1.9 million recorded in 2024.
  • Year-over-year, Current Leases crashed 57.24% in 2022 and then skyrocketed 706.99% in 2023.
  • Barinthus Biotherapeutics' Current Leases stood at $433000.0 in 2022, then skyrocketed by 312.24% to $1.8 million in 2023, then increased by 7.56% to $1.9 million in 2024, then rose by 5.36% to $2.0 million in 2025, then dropped by 0.89% to $2.0 million in 2026.
  • According to Business Quant data, Current Leases over the past three periods came in at $2.0 million, $2.0 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.